• +1-646-491-9876
    • +91-20-67278686

    Search

    Rectal Cancer - Pipeline Review, H1 2017

    Rectal Cancer - Pipeline Review, H1 2017

    • Report Code ID: RW0001709444
    • Category Pharmaceuticals
    • No. of Pages 130
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Rectal Cancer - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Rectal Cancer - Pipeline Review, H1 2017, provides an overview of the Rectal Cancer (Oncology) pipeline landscape.

    Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The risk factors for developing rectal cancer are increasing age, smoking, family history of colon or rectal cancer, high-fat diet and/or a diet mostly from animal sources and personal or family history of polyps or colorectal cancer. Rectal cancer commonly spreads to organs such as the liver and the lungs. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting. Rectal cancer treatment includes surgery, radiation therapy or chemotherapy, or a combination of these approaches

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Rectal Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Rectal Cancer (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Rectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 5, 5 and 1 respectively.

    Rectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Rectal Cancer (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Rectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Rectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Rectal Cancer (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Rectal Cancer (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Rectal Cancer (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Rectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Rectal Cancer - Overview
    Rectal Cancer - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Rectal Cancer - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Rectal Cancer - Companies Involved in Therapeutics Development
    AbbVie Inc
    Advaxis Inc
    Cerulean Pharma Inc
    GlaxoSmithKline Plc
    Karyopharm Therapeutics Inc
    Peregrine Pharmaceuticals Inc
    Regeneron Pharmaceuticals Inc
    Taiwan Liposome Company Ltd
    Targovax ASA
    Rectal Cancer - Drug Profiles
    axalimogene filolisbac - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bavituximab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CRLX-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ganetespib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-2256098 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NM-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ONCOS-102 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    selinexor - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TLC-388 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    veliparib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ziv-aflibercept - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Rectal Cancer - Dormant Projects
    Rectal Cancer - Product Development Milestones
    Featured News & Press Releases
    Apr 23, 2014: Abbvie To Present Data On Veliparib At The 2014 American Society Of Clinical Oncology Annual Meeting
    Nov 10, 2011: Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells To Chemoradiotherapy
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Rectal Cancer, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Rectal Cancer - Pipeline by AbbVie Inc, H1 2017
    Rectal Cancer - Pipeline by Advaxis Inc, H1 2017
    Rectal Cancer - Pipeline by Cerulean Pharma Inc, H1 2017
    Rectal Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
    Rectal Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2017
    Rectal Cancer - Pipeline by Peregrine Pharmaceuticals Inc, H1 2017
    Rectal Cancer - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
    Rectal Cancer - Pipeline by Taiwan Liposome Company Ltd, H1 2017
    Rectal Cancer - Pipeline by Targovax ASA, H1 2017
    Rectal Cancer - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Rectal Cancer, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AbbVie Inc
    Advaxis Inc
    Cerulean Pharma Inc
    GlaxoSmithKline Plc
    Karyopharm Therapeutics Inc
    Peregrine Pharmaceuticals Inc
    Regeneron Pharmaceuticals Inc
    Taiwan Liposome Company Ltd
    Targovax ASA

    Request for Sample

    Report Url http://www.reportsweb.com//rectal-cancer-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//rectal-cancer-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//rectal-cancer-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments